Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Johnson & Johnson Down Over 4% After Seeking Drug Approval -- Data Talk

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/12/2019 | 12:38pm EDT

Johnson & Johnson (JNJ) is currently at $134.01, down $6.10 or 4.35%

-- Would be lowest close since June 4, 2019, when it closed at $133.73

-- On pace for largest percent decrease since Dec. 14, 2018, when it fell 10.04%

-- Earlier Friday, The Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ) said it submitted an application with the U.S. Food and Drug Administration seeking approval of its new subcutaneous formulation of Darzalex, or daratumumab, for certain patients with multiple myeloma

-- Credit Suisse initiated Johnson & Johnson at outperform with a price target of $156.00/share, Benzinga reported

-- Currently down three consecutive days; down 5.23% over this period

-- Worst three day stretch since the three days ending May 29, 2019, when it fell 6.05%

-- Down 3.78% month-to-date

-- Up 3.84% year-to-date

-- Down 9.54% from its all-time closing high of $148.14 on Jan. 22, 2018

-- Up 6.42% from 52 weeks ago (July 13, 2018), when it closed at $125.93

-- Down 9.35% from its 52 week closing high of $147.84 on Dec. 13, 2018

-- Up 9.09% from its 52 week closing low of $122.84 on Dec. 24, 2018

-- Traded as low as $132.97; lowest intraday level since June 4, 2019, when it hit $132.58

-- Down 5.1% at today's intraday low; largest intraday percent decrease since May 29, 2019, when it fell as much as 6.24%

-- Worst performer in the DJIA today

-- Second worst performer in the S&P 500 today

-- Subtracted 41.36 points from the DJIA so far today

All data as of 12:12:23 PM

Source: Dow Jones Market Data, FactSet

Stocks mentioned in the article
ChangeLast1st jan.
DJ INDUSTRIAL -0.25% 27154.2 Delayed Quote.16.40%
JOHNSON & JOHNSON -1.33% 130.31 Delayed Quote.2.34%
NASDAQ 100 -0.88% 7834.896756 Delayed Quote.25.23%
NASDAQ COMP. -0.74% 8146.488965 Delayed Quote.24.46%
S&P 500 -0.62% 2976.61 Delayed Quote.19.48%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
10:51pJOHNSON & JOHNSON INVESTIGATION UPDA : Kahn Swick & Foti, LLC Continues to Inves..
BU
07:31aJOHNSON & JOHNSON : J&J's Janssen Seeks Europe OK For Subcutaneous Darzalex in M..
DJ
07/18JOHNSON & JOHNSON : Oklahoma County seeking lawsuit against opioid manufacturers
AQ
07/18JOHNSON & JOHNSON : DRC rejects clinical trial for experimental Ebola vaccine
AQ
07/17JOHNSON & JOHNSON : Extends Long-Standing Donation Program to Support Global Eff..
AQ
07/17GENMAB : Announces Net Sales of DARZALEX for Second Quarter of 2019
AQ
07/17JOHNSON & JOHNSON : 's Baltic net profits down 42% to EUR 1.2 million
AQ
07/17J&J Lifts Forecast As Suits Weigh On Its Shares -- WSJ
DJ
07/17JOHNSON & JOHNSON : Pharma strength boosts Johnson & Johnson profit
AQ
07/16Wall Street slips as bank earnings, Trump trade comments weigh
RE
More news
Financials (USD)
Sales 2019 81 594 M
EBIT 2019 25 389 M
Net income 2019 18 319 M
Debt 2019 6 116 M
Yield 2019 2,87%
P/E ratio 2019 19,4x
P/E ratio 2020 17,2x
EV / Sales2019 4,32x
EV / Sales2020 4,05x
Capitalization 346 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 149,00  $
Last Close Price 130,31  $
Spread / Highest target 29,7%
Spread / Average Target 14,3%
Spread / Lowest Target -4,84%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON2.34%350 653
PFIZER-2.08%239 061
ROCHE HOLDING LTD.11.42%234 924
ROCHE HOLDING13.37%234 924
NOVARTIS24.46%217 699
MERCK AND COMPANY8.22%212 897